Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)
- Conditions
- Severe Uncontrolled Atopic Dermatitis
- Registration Number
- NCT05466578
- Lead Sponsor
- Pfizer
- Brief Summary
Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis
- Detailed Description
In Expanded Access, treating physicians are the Sponsor.
Expanded Access requests from treating physicians may be submitted at www.pfizercares.com ; availability will depend on location/country.
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method